DRG Market Assessment
Access expert curated disease market assessment insights into treatment dynamics, unmet need, competitive shifts, and access factors to size opportunities and shape confident market strategy.
Indication level market assessment revealing what drives today’s disease markets and what comes next
DRG Market Assessment delivers expert curated disease market intelligence that explains how markets behave in the real world. By integrating treatment pathways, competitive dynamics, physician decision drivers, unmet need, and access considerations, it helps life sciences teams evaluate opportunity, refine positioning, and anticipate how markets will evolve.
Drive better decisions with market assessment insights
See the true drivers of disease markets
Get clarity on how diseases are treated today—across treatment pathways, prescribing behavior, unmet need, competitive pressure, access considerations, and physician-reported decision drivers. Understand what’s shaping the market now and what will matter next.
Size and prioritize opportunities with confidence
Leverage deep, indication‑level insights to evaluate market potential, quantify patient opportunity, and identify the most strategically valuable segments and indications for investment.
Stay ahead of competitive and therapeutic shifts
Track emerging therapies, biosimilar disruption, pipeline evolution, and shifting standards of care to understand future competitive market dynamics. Anticipate threats and opportunities early so your strategy stays aligned with where the market is headed—not where it was.
Comprehensive disease market assessment across treatment and competition
Explore expert curated analysis—from disease market context and treatment patterns to competitive positioning and access dynamics—designed to guide commercial strategy across the product lifecycle.
Disease landscape and market outlook
Indication‑level disease market assessment covering disease burden, epidemiology, treatment evolution, competitive activity, biosimilar impact, and long‑range forecasting to support opportunity assessment and lifecycle planning.
Solutions included:
- Disease landscape and forecast
- Niche and rare disease landscape and forecast
- Biosimilars intelligence
- China in‑depth
- Executive insights (on‑demand)
Treatment, physician and access insights
Understand how treatment decisions are made in real‑world clinical practice—and how access, reimbursement, and physician behavior shape adoption. Understand real‑world treatment patterns and the clinical and non-clinical decision drivers shaping brand adoption, prescribing behavior, sequencing, unmet need, and access and reimbursement dynamics.
Solutions included:
- Current treatment: Physician insights
- Unmet need
- Treatment algorithms: Claims data analysis
- Treatment sequencing
- Access and reimbursement
Competitive strategy and market impact
Anticipate competitive threats and positioning opportunities as markets evolve. Anticipate how competitive entry, therapeutic innovation, and standard‑of‑care evolution reshape market share, patient flow, and commercial opportunity.
Solutions included:
- Biosimilars intelligence
- Treatment sequencing
- Treatment algorithms: Claims data analysis
- Disease landscape and forecast
Questions we help you answer with confidence
Market assessment questions that define confident commercial and brand strategy.
- What clinical, competitive, and behavioral factors shape real‑world treatment decisions in this indication?
- Which patient segments and indications offer the strongest commercial opportunity for our brand?
- How will emerging therapies, biosimilars, and evolving standards of care change competitive positioning?
- Where are the unmet needs that matter most to physicians, and what trade-offs are they willing to make in their prescribing decision—and how can we differentiate?
- How do we assess opportunity and differentiate in rare or niche indications where data is limited and markets are still emerging?
Why leading teams rely on DRG Market Assessment?
Expert curated insights informed by extensive primary market research—combining KOL interviews, physician, payer, and market surveys conducted annually
10-year
20+
50+
14
75+
Resources
Seven companies forging new paths in women’s health
Women’s health: from neglect to global investment priority For decades, women’s health has been underfunded and understudied, despite women representing half the global population. Conditions that disproportionately affect women, such…
Frequently asked questions
A disease market assessment evaluates how a disease market functions in practice, including treatment patterns, competitive dynamics, physician and payer decision drivers, unmet need, and access factors. It helps life sciences teams understand not just the size of an opportunity, but how and where value will be realized.
DRG Market Assessment reveals how physicians treat patients across lines of therapy, what clinical and practical factors drive prescribing decisions, and which barriers influence brand adoption. This includes insights into treatment pathways, sequencing, unmet need, market access factors, and physician‑reported decision drivers—helping teams understand why the market behaves the way it does.
Epidemiology Intelligence provides population size, segmentation, incidence, prevalence, and long‑range forecasts, giving teams a defensible foundation for market sizing. Market Assessment builds on that by uncovering how the market actually behaves now and, in the future, —including evolving patient shares, treatment patterns, competitive dynamics, unmet need, and physician decision drivers.
Most teams use both together: epidemiology answers “How big is the opportunity?”, while Market Assessment answers “How is the opportunity playing out in practice?”
Market Assessment pinpoints the most attractive segments and indications by integrating treatment dynamics, competitive evolution, biosimilar impact, and unmet need. This helps teams prioritize opportunities, identify areas for differentiation, refine positioning, and decide where to focus investment for maximum impact.
Insights are updated on a regular cadence—typically annually or semi‑annually—depending on the therapy area and product. Updates reflect new clinical evidence, changes in treatment pathways, biosimilar launches, guideline updates, and shifts in competitive dynamics, ensuring teams have an accurate view of evolving market realities. Additionally, annual updates always reflect newly conducted primary market research, refreshed, validated forecasts, and event-driven updates on a regular basis.
DRG Market Assessment is a core component of the Disease Intelligence & Analytics platform, focused on how diseases are treated and how markets evolve. While the broader platform brings together multiple types of disease-level insight, Market Assessment provides deep visibility into treatment patterns, competitive dynamics, and commercial opportunities—helping teams guide positioning and strategy within specific disease areas.
Explore complementary insights and solutions
Expand your view with related intelligence that strengthens strategic decisions.
